288 related articles for article (PubMed ID: 18782850)
21. Glycogen stored in skeletal but not in cardiac muscle in acid alpha-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme.
Raben N; Jatkar T; Lee A; Lu N; Dwivedi S; Nagaraju K; Plotz PH
Mol Ther; 2002 Nov; 6(5):601-8. PubMed ID: 12409258
[TBL] [Abstract][Full Text] [Related]
22. Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II.
Hermans MM; van Leenen D; Kroos MA; Beesley CE; Van Der Ploeg AT; Sakuraba H; Wevers R; Kleijer W; Michelakakis H; Kirk EP; Fletcher J; Bosshard N; Basel-Vanagaite L; Besley G; Reuser AJ
Hum Mutat; 2004 Jan; 23(1):47-56. PubMed ID: 14695532
[TBL] [Abstract][Full Text] [Related]
23. Approach to gene therapy of glycogenosis type II (Pompe disease).
Poenaru L
Mol Genet Metab; 2000 Jul; 70(3):163-9. PubMed ID: 10924270
[TBL] [Abstract][Full Text] [Related]
24. New insights into therapeutic options for Pompe disease.
Richard E; Douillard-Guilloux G; Caillaud C
IUBMB Life; 2011 Nov; 63(11):979-86. PubMed ID: 22002928
[TBL] [Abstract][Full Text] [Related]
25. Chemical chaperones improve transport and enhance stability of mutant alpha-glucosidases in glycogen storage disease type II.
Okumiya T; Kroos MA; Vliet LV; Takeuchi H; Van der Ploeg AT; Reuser AJ
Mol Genet Metab; 2007 Jan; 90(1):49-57. PubMed ID: 17095274
[TBL] [Abstract][Full Text] [Related]
26. Increased occurrence of cleft lip in glycogen storage disease type II (GSDII): exclusion of a contiguous gene syndrome in two patients by presence of intragenic mutations including a novel nonsense mutation Gln58Stop.
Huie ML; Kasper JS; Arn PH; Greenberg CR; Hirschhorn R
Am J Med Genet; 1999 Jul; 85(1):5-8. PubMed ID: 10377006
[TBL] [Abstract][Full Text] [Related]
27. Correction/mutation of acid alpha-D-glucosidase gene by modified single-stranded oligonucleotides: in vitro and in vivo studies.
Lu IL; Lin CY; Lin SB; Chen ST; Yeh LY; Yang FY; Au LC
Gene Ther; 2003 Oct; 10(22):1910-6. PubMed ID: 14502220
[TBL] [Abstract][Full Text] [Related]
28. Systemic Delivery of AAVB1-GAA Clears Glycogen and Prolongs Survival in a Mouse Model of Pompe Disease.
Keeler AM; Zieger M; Todeasa SH; McCall AL; Gifford JC; Birsak S; Choudhury SR; Byrne BJ; Sena-Esteves M; ElMallah MK
Hum Gene Ther; 2019 Jan; 30(1):57-68. PubMed ID: 29901418
[TBL] [Abstract][Full Text] [Related]
29. Pompe disease: a review of the current diagnosis and treatment recommendations in the era of enzyme replacement therapy.
Katzin LW; Amato AA
J Clin Neuromuscul Dis; 2008 Jun; 9(4):421-31. PubMed ID: 18525427
[TBL] [Abstract][Full Text] [Related]
30. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors.
Fraites TJ; Schleissing MR; Shanely RA; Walter GA; Cloutier DA; Zolotukhin I; Pauly DF; Raben N; Plotz PH; Powers SK; Kessler PD; Byrne BJ
Mol Ther; 2002 May; 5(5 Pt 1):571-8. PubMed ID: 11991748
[TBL] [Abstract][Full Text] [Related]
31. Correlation of acid alpha-glucosidase and glycogen content in skin fibroblasts with age of onset in Pompe disease.
Umapathysivam K; Hopwood JJ; Meikle PJ
Clin Chim Acta; 2005 Nov; 361(1-2):191-8. PubMed ID: 15993875
[TBL] [Abstract][Full Text] [Related]
32. Defect in degradation of glycogenin-exposed residual glycogen in lysosomes is the fundamental pathomechanism of Pompe disease.
Zhang N; Liu F; Zhao Y; Sun X; Wen B; Lu JQ; Yan C; Li D
J Pathol; 2024 May; 263(1):8-21. PubMed ID: 38332735
[TBL] [Abstract][Full Text] [Related]
33. Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy.
van der Beek NA; Hagemans ML; van der Ploeg AT; Reuser AJ; van Doorn PA
Acta Neurol Belg; 2006 Jun; 106(2):82-6. PubMed ID: 16898258
[TBL] [Abstract][Full Text] [Related]
34. Helios gene gun particle delivery for therapy of acid maltase deficiency.
Martiniuk F; Chen A; Mack A; Donnabella V; Slonim A; Bulone L; Arvanitopoulos E; Raben N; Plotz P; Rom WN
DNA Cell Biol; 2002 Oct; 21(10):717-25. PubMed ID: 12443541
[TBL] [Abstract][Full Text] [Related]
35. Hyaluronidase increases the biodistribution of acid alpha-1,4 glucosidase in the muscle of Pompe disease mice: an approach to enhance the efficacy of enzyme replacement therapy.
Matalon R; Surendran S; Campbell GA; Michals-Matalon K; Tyring SK; Grady J; Cheng S; Kaye E
Biochem Biophys Res Commun; 2006 Nov; 350(3):783-7. PubMed ID: 17027913
[TBL] [Abstract][Full Text] [Related]
36. Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors.
Mah C; Pacak CA; Cresawn KO; Deruisseau LR; Germain S; Lewis MA; Cloutier DA; Fuller DD; Byrne BJ
Mol Ther; 2007 Mar; 15(3):501-7. PubMed ID: 17245350
[TBL] [Abstract][Full Text] [Related]
37. [Treatment of Pompe's disease with recombinant enzymes].
Van Hove JL
Verh K Acad Geneeskd Belg; 1998; 60(4):347-57. PubMed ID: 9883081
[TBL] [Abstract][Full Text] [Related]
38. Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy.
Winkel LP; Kamphoven JH; van den Hout HJ; Severijnen LA; van Doorn PA; Reuser AJ; van der Ploeg AT
Muscle Nerve; 2003 Jun; 27(6):743-51. PubMed ID: 12766987
[TBL] [Abstract][Full Text] [Related]
39. Reduction of Autophagic Accumulation in Pompe Disease Mouse Model Following Gene Therapy.
McCall AL; Stankov SG; Cowen G; Cloutier D; Zhang Z; Yang L; Clement N; Falk DJ; Byrne BJ
Curr Gene Ther; 2019; 19(3):197-207. PubMed ID: 31223086
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of Readministration of a Recombinant Adeno-Associated Virus Vector Expressing Acid Alpha-Glucosidase in Pompe Disease: Preclinical to Clinical Planning.
Corti M; Cleaver B; Clément N; Conlon TJ; Faris KJ; Wang G; Benson J; Tarantal AF; Fuller D; Herzog RW; Byrne BJ
Hum Gene Ther Clin Dev; 2015 Sep; 26(3):185-93. PubMed ID: 26390092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
